Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties
Version of Record online: 8 FEB 2013
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
European Journal of Immunology
Volume 43, Issue 3, pages 826–837, March 2013
How to Cite
Rodríguez-Zhurbenko, N., Martínez, D., Blanco, R., Rondón, T., Griñán, T. and Hernández, A. M. (2013), Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties. Eur. J. Immunol., 43: 826–837. doi: 10.1002/eji.201242693
- Issue online: 11 MAR 2013
- Version of Record online: 8 FEB 2013
- Accepted manuscript online: 14 JAN 2013 09:04AM EST
- Manuscript Accepted: 8 JAN 2013
- Manuscript Revised: 19 NOV 2012
- Manuscript Received: 22 MAY 2012
- Center of Molecular Immunology
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Figure S1. Level of anti-NeuGcGM3 antibodies in male and female healthy humans is similar.
Figure S2. Total amount of IgM and IgG in healthy donors’ sera does not change with age.
Figure S3. Presence of NeuGcGM3 on L1210 cells.
Figure S4. Healthy humans’ sera induced complement mediated cell death to NeuGcGM3 expressing tumor cells.
Figure S5. Induced complement independent cell death positively correlates with both the levels of anti-NeuGcGM3 antibodies and tumor cell binding.
Figure S6. Incubation of L1210 cells with cytotoxic healthy humans’ sera did not induce caspase 3 activation.
Figure S7. Anti-NeuGcGM3 Abs obtained from NSCLC patients demonstrate specific binding.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.